KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial.

Donald L Gilbert, Sarah D Atkinson, David J B Kim, Meredith M Miller, Patricia M Rice, John A Flatt, George B Karkanias, Frederick E Munschauer, Richard M Bittman, Stephen P Wanaski, Timothy M Cunniff, Kinga K Tomczak

JAMA Neurol 83(7) 645-653

PMID42189524
PMCIDPMC13213590
DOI10.1001/jamaneurol.2026.1431
发表日期2026-05-26
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Current Tourette syndrome (TS) pharmacotherapy is hindered by adverse effects and high discontinuation rates. OBJECTIVE: To evaluate the safety and maintenance of effect of ecopipam, a selective dopamine D1 receptor antagonist, for up to 24 weeks for TS. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a phase 3, double-blind, placebo-controlled, randomized withdrawal study conducted between January 31, 2023, and February 4, 2025. Participants were enrolled at 77 sites in 12 countries. Individuals 6 years and older with TS were eligible. INTERVENTION: In the 12-week, open-label period, ecopipam was titrated over 3 to 4 weeks (target dose, 1.8 mg/kg per day). Responders (≥25% improvement in Yale Global Tic Severity Scale Total Tic Score [YGTSS-TTS] at weeks 8 and 12) were randomized to continue ecopipam or taper to placebo for the 12-week double-blind period. MAIN OUTCOMES AND MEASURES: Time to relapse (≥50% loss of open-label period YGTSS-TTS improvement) in participants aged 6 to 18 years (primary) and adults (exploratory). RESULTS: The trial enrolled 216 participants (n = 167 [77.3%] pediatric; 146 [67.6%] male and 70 [32.4%] female) to the open-label ecopipam period. Of these, 43 pediatric participants (mean [SD] age, 14.3 [5.5] years) and 8 adult participants were randomized to receive ecopipam; 47 pediatric (mean [SD] age, 14.0 [5.8] years) and 6 adult participants were randomized to receive placebo. Ecopipam significantly reduced the relapse risk vs placebo in pediatric participants (hazard ratio [HR], 0.47; 95% CI, 0.26-0.84; P = .008; n = 90). In adults, the effect was directionally similar (HR, 0.51; 95% CI, 0.11-2.30; P = .37; n = 14) but not significant. The most frequently reported adverse events with ecopipam (open-label and double-blind periods) were somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]). Ecopipam did not have a clinically meaningful impact on weight, metabolic parameters, or psychiatric scale measures. Drug-induced movement disorders were not observed. CONCLUSIONS AND RELEVANCE: Ecopipam maintained clinically meaningful TS symptom improvements and was well tolerated for up to 24 weeks. Adverse events primarily affected the central nervous system. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05615220.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2.. Kaplan-Meier Curves for Time to Relapse in the Pediatric Population (A) and Overall Population (B) From Randomization (Week 12) The plus (+) sign indicates censored data. Relapse was defined as ≥50% loss of improvement in Yale Global Tic Severity Scale Total Tic Score previously observed from baseline to week 12, initiation of additional medications for Tourette syndrome symptoms, or hospitalization related to worsening symptoms. HR indicates hazard ratio.

Pediatric_population

time to relapse

Figure 2 · Panel Pediatric_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Pediatric_population 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
Overall_population

time to relapse

Figure 2 · Panel Overall_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_population 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Participant Disposition mITT indicates modified intent-to-treat. a Investigator decision, protocol deviation, or other. b Received ≥1 dose of study drug. c ≥25% Improvement from baseline in Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS) at both weeks 8 and 12. d Study participation ended when 49 pediatric relapse events occurred. e Investigator decision, protocol deviation, nonadherence to study drug, or other. f Received ≥1 dose of study drug after random assignment. g ≥50% Loss of improvement in YGTSS-TTS previously observed from baseline to week 12, initiation of additional medications for Tourette syndrome symptoms, or hospitalization related to worsening symptoms. h Withdrawal of consent, withdrawal by parent/caregiver, or other.
非 KM Figure